CHAPEL HILL, NC (April 14, 2021) — Devana Solutions, LLC is pleased to announce their newest client-partnership with the Icon Group, Australia’s largest dedicated provider of private cancer care. Icon Group has an extensive clinical trials program, and through its continuing growth, Devana’s IGNITE platform will help support their ongoing success.
Icon Research provides patients and clinicians with access to new and emerging advances in cancer treatment, conducting trials in hematology, medical oncology, and radiation oncology across a wide range of cancer types. Within the private setting, Icon Research has an unparalleled track record of participating in national and international clinical trials, including Phase I to IV, pharmaceutical industry-sponsored, and collaborative studies undertaken in partnership with various universities and collaborative groups.
Alongside the extensive clinical trials program, Icon Research conducts in-house clinical studies across clinical hematology, medical oncology, radiation oncology, nursing, pharmacy, and medical physics. This research provides professional development opportunities to Icon investigators and the wider Icon team and continues to pave the way for new advances in quality cancer care.
In 2020, Icon Research initiated an internal restructure to better support their expected growth, which led them to Devana Solutions. Devana’s IGNITE platform will help increase the ease and efficiency in research feasibility and start-up processes. This platform allows pre-CTMS data collection to occur, standardized reporting, pipeline tracking, and automated workflows, all of which reduce the time it takes for a trial to begin. IGNITE integrates with Icon’s preferred CTMS, RealTime, allowing a seamless transfer of a trial from feasibility and start-up assessment into an active and financially tracked clinical trial. This integration removes the need for duplicate data entry and prevents the loss of important assessment data previously collected.
Devana Solutions supports some of the leading cancer research organizations worldwide, and the Icon Group is no exception. Their tireless dedication to combatting such an invasive and devastating disease is evident in all they do. Devana is honored to help support their efforts in advancing cancer therapies through their innovative and intuitive platforms.
ABOUT ICON GROUP:
Icon Group is Australia’s largest dedicated private provider of cancer care with a growing reach into Asia and New Zealand. The Group is built on a strong but simple vision to deliver the best care possible to as many people as possible, as close to home as possible.
Icon Group’s integrated, end-to-end service model leverages the strengths of a diverse, multi-disciplinary team to achieve this mission. Their businesses encompass all aspects of quality cancer care, including treatment delivery, pharmacy, and chemotherapy compounding. To learn more, visit https://icongroup.global.
ABOUT DEVANA SOLUTIONS LLC:
Devana Solutions®, LLC is a cloud SaaS provider driven by a core belief that data transparency through technology is critical to the selection of top-performing research sites to align with pharmaceutical Sponsors and CROs to reduce drug development costs and cure disease.
Devana Solutions® flagship platform, Devana IGNITE, allows integrated site networks and research organizations to standardize workflows, particularly in study startup, across site functions while allowing for the capture and display of performance metrics for dashboarding and analytics beyond site CTMS. Devana PROPEL extends performance data transparency across Academic Research Institutions or an expanded network of owned and affiliated investigative sites. Devana IQ allows for the sharing of performance data and documents in real-time between investigative site and Sponsor or CRO stakeholders. To learn more, visit http://devanasolutions.com.